This clinical study adopted a single-arm, open, single-centertrial design. The purpose of
this study was to evaluate the safety and tolerability, PK characteristics, shedding and
immune response characteristics of BCG for therapeutic use developed by Anhui Zhifei Longcom
Biologic Pharmacy Co., Ltd. in patients aged 18 and over after transethral resection of
non-muscular invasive bladder cancer.